Role of N6-methyladenosine Methylation in Head and Neck Cancer and Its Regulation of Innate Immune Pathways

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Oct 15

PMID 39403369

Authors

Luhong Cao

Guixiang Huang

Jiangang Fan

Xingren Liu

Zhiyue Ma

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (m6A) is considered the most prevalent methylation modification in messenger RNA (mRNA) that critically impacts head and neck cancer (HNC) pathogenesis and development. Alterations of m6A methylation related proteins are closely related to the progression, therapeutic effect, and prognosis of HNC. The human innate immune system activates immune pathways through pattern recognition receptors, which can not only resist pathogen infection, but also play a vital role in tumor immunity. Emerging evidence has confirmed that m6A methylation affects the activation of innate immune pathways such as TLR, cGAS-STING, and NLR by regulating RNA metabolism, revealing its potential mechanisms in the innate immune response of tumor cells. However, the relevant research is still in its infancy. This review elaborates the biological significance of RNA m6A methylation in HNC and discusses its potential regulatory relationship with TLR, cGAS-STING, and NLR pathways, providing a new perspective for in-depth understanding of the role of RNA methylation in the innate immune mechanism and therapeutic application of HNC.

Citing Articles

Identification of diagnostic biomarkers and molecular subtype analysis associated with m6A in Tuberculosis immunopathology using machine learning.

Ding S, Gao J, Huang C, Zhou Y, Yang Y, Cai Z Sci Rep. 2024; 14(1):29982.

PMID: 39622968 PMC: 11612281. DOI: 10.1038/s41598-024-81790-4.

References

Wang X, Zhao B, Roundtree I, Lu Z, Han D, Ma H . N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015; 161(6):1388-99. PMC: 4825696. DOI: 10.1016/j.cell.2015.05.014. View

Viculin J, Degoricija M, Vilovic K, Gabela I, Frankovic L, Vrdoljak E . Elevated Tumor Cell-Intrinsic STING Expression in Advanced Laryngeal Cancer. Cancers (Basel). 2023; 15(13). PMC: 10341367. DOI: 10.3390/cancers15133510. View

Yoon H, Ahn M, Kwon S, Kim D, Lee J, Yoon J . Nucleotide-binding oligomerization domain 2 (NOD2) activation induces apoptosis of human oral squamous cell carcinoma cells. J Oral Pathol Med. 2015; 45(4):262-7. DOI: 10.1111/jop.12354. View

Chen B, Huang Y, He S, Yu P, Wu L, Peng H . N-methyladenosine modification in 18S rRNA promotes tumorigenesis and chemoresistance via HSF4b/HSP90B1/mutant p53 axis. Cell Chem Biol. 2023; 30(2):144-158.e10. DOI: 10.1016/j.chembiol.2023.01.006. View

Wang X, Fu X, Zhang J, Xiong C, Zhang S, Lv Y . Identification and validation of mA RNA methylation regulators with clinical prognostic value in Papillary thyroid cancer. Cancer Cell Int. 2020; 20:203. PMC: 7260751. DOI: 10.1186/s12935-020-01283-y. View

Bailey A, Batista P, Gold R, Chen Y, de Rooij D, Chang H . The conserved RNA helicase YTHDC2 regulates the transition from proliferation to differentiation in the germline. Elife. 2017; 6. PMC: 5703642. DOI: 10.7554/eLife.26116. View

Zhu C, Li J, Yao M, Fang C . Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma. BMC Oral Health. 2021; 21(1):506. PMC: 8501566. DOI: 10.1186/s12903-021-01813-8. View

Wang W, Ding Y, Zhao Y, Li X . m6A reader IGF2BP2 promotes lymphatic metastasis by stabilizing DPP4 in papillary thyroid carcinoma. Cancer Gene Ther. 2023; 31(2):285-299. DOI: 10.1038/s41417-023-00702-2. View

Wang X, Zhi M, Zhao W, Deng J . HNRNPA2B1 promotes oral squamous cell carcinogenesis via mA-dependent stabilization of FOXQ1 mRNA stability. IUBMB Life. 2024; 76(7):437-450. DOI: 10.1002/iub.2808. View

10.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

11.

Vanpouille-Box C, Demaria S, Formenti S, Galluzzi L . Cytosolic DNA Sensing in Organismal Tumor Control. Cancer Cell. 2018; 34(3):361-378. DOI: 10.1016/j.ccell.2018.05.013. View

12.

Zhang P, He Q, Lei Y, Li Y, Wen X, Hong M . mA-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Dis. 2018; 9(12):1169. PMC: 6281568. DOI: 10.1038/s41419-018-1224-3. View

13.

Yokota S, Okabayashi T, Rehli M, Fujii N, Amano K . Helicobacter pylori lipopolysaccharides upregulate toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. Infect Immun. 2009; 78(1):468-76. PMC: 2798195. DOI: 10.1128/IAI.00903-09. View

14.

Ullah M, Sweet M, Mansell A, Kellie S, Kobe B . TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target. J Leukoc Biol. 2016; 100(1):27-45. DOI: 10.1189/jlb.2RI1115-531R. View

15.

Luo X, Donnelly C, Gong W, Heath B, Hao Y, Donnelly L . HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Invest. 2019; 130(4):1635-1652. PMC: 7108911. DOI: 10.1172/JCI129497. View

16.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

17.

Chattopadhyay S, Marques J, Yamashita M, Peters K, Smith K, Desai A . Viral apoptosis is induced by IRF-3-mediated activation of Bax. EMBO J. 2010; 29(10):1762-73. PMC: 2876960. DOI: 10.1038/emboj.2010.50. View

18.

Szczepanski M, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A . Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009; 69(7):3105-13. PMC: 3708458. DOI: 10.1158/0008-5472.CAN-08-3838. View

19.

Marcus A, Mao A, Lensink-Vasan M, Wang L, Vance R, Raulet D . Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity. 2018; 49(4):754-763.e4. PMC: 6488306. DOI: 10.1016/j.immuni.2018.09.016. View

20.

Li Q, Wang Y, Meng X, Wang W, Duan F, Chen S . METTL16 inhibits papillary thyroid cancer tumorigenicity through mA/YTHDC2/SCD1-regulated lipid metabolism. Cell Mol Life Sci. 2024; 81(1):81. PMC: 10857971. DOI: 10.1007/s00018-024-05146-x. View